XML 40 R24.htm IDEA: XBRL DOCUMENT
v3.21.1

Note 16 - Segment Data | 12 Months Ended
--- | ---
Mar. 31, 2021
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | Note 16. Segment Data Segment information is prepared on the same basis that our CEO, who is our Chief Operating Decision Maker, uses to manage the segments, evaluate financial results, and make key operating decisions. We have four reportable segments based primarily upon product type: Sterilization and Disinfection Control, Instruments, Biopharmaceutical Development, and Continuous Monitoring. When determining the reportable segments, we aggregated operating segments based on their similar economic and operating characteristics. We evaluate the performance of our operating segments based on revenues, organic revenues growth, and gross margin. The accounting policies of the operating segments are the same as those described in Note 1. "Description of Business and Summary of Significant Accounting Policies." The following tables set forth our segment information:
|  | Year Ended March 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Total revenues (a) |  |  |  |  |  |  |  |  |  |  |  |
Sterilization and Disinfection Control |  | $ | 53,119 |  |  | $ | 49,660 |  |  | $ | 46,297 |
Instruments |  |  | 32,465 |  |  |  | 37,984 |  |  |  | 36,125 |
Biopharmaceutical Development |  |  | 33,892 |  |  |  | 13,851 |  |  |  | - |
Continuous Monitoring |  |  | 14,461 |  |  |  | 13,729 |  |  |  | 13,806 |
Reportable segment revenues |  |  | 133,937 |  |  |  | 115,224 |  |  |  | 96,228 |
Corporate and Other (b) |  |  | - |  |  |  | 2,463 |  |  |  | 6,907 |
Total revenues (a) |  | $ | 133,937 |  |  | $ | 117,687 |  |  | $ | 103,135 |
Gross profit (loss) |  |  |  |  |  |  |  |  |  |  |  |
Sterilization and Disinfection Control |  | $ | 39,870 |  |  | $ | 35,797 |  |  | $ | 31,861 |
Instruments |  |  | 20,158 |  |  |  | 24,247 |  |  |  | 22,866 |
Biopharmaceutical Development |  |  | 21,035 |  |  |  | 382 |  |  |  | - |
Continuous Monitoring |  |  | 5,954 |  |  |  | 4,518 |  |  |  | 5,582 |
Reportable segment gross profit |  |  | 87,017 |  |  |  | 64,944 |  |  |  | 60,309 |
Corporate and Other (b) |  |  | (3 | ) |  |  | 418 |  |  |  | 607 |
Gross profit |  | $ | 87,014 |  |  | $ | 65,362 |  |  | $ | 60,916 |
Reconciling Items: |  |  |  |  |  |  |  |  |  |  |  |
Operating expenses |  |  | 74,656 |  |  |  | 57,439 |  |  |  | 51,135 |
Operating income |  |  | 12,358 |  |  |  | 7,923 |  |  |  | 9,781 |
Nonoperating expense, net |  |  | 10,055 |  |  |  | 4,061 |  |  |  | 1,158 |
Earnings before income taxes |  | $ | 2,303 |  |  | $ | 3,862 |  |  | $ | 8,623 |
| (a) | Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
| (b) | Non-reportable operating segments (including our Cold Chain Packaging Division which ceased operations during the year ended March 31, 2020) and unallocated corporate expenses are reported within Corporate and Other.
|  | Year Ended March 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Depreciation and amortization |  |  |  |  |  |  |  |  |  |  |  |
Sterilization and Disinfection Control |  | $ | 857 |  |  | $ | 902 |  |  | $ | 902 |
Instruments |  |  | 164 |  |  |  | 179 |  |  |  | 207 |
Biopharmaceutical Development |  |  | 1,427 |  |  |  | 672 |  |  |  | - |
Continuous Monitoring |  |  | 256 |  |  |  | 328 |  |  |  | 272 |
Reportable segment depreciation and amortization |  |  | 2,704 |  |  |  | 2,081 |  |  |  | 1,381 |
Corporate and Other (c) |  |  | 14,956 |  |  |  | 10,909 |  |  |  | 8,047 |
Depreciation and amortization |  | $ | 17,660 |  |  | $ | 12,990 |  |  | $ | 9,428 |
Capital expenditures |  |  |  |  |  |  |  |  |  |  |  |
Sterilization and Disinfection Control |  | $ | 136 |  |  | $ | 291 |  |  | $ | 384 |
Instruments |  |  | 128 |  |  |  | 165 |  |  |  | 56 |
Biopharmaceutical Development |  |  | 539 |  |  |  | 233 |  |  |  | - |
Continuous Monitoring |  |  | 40 |  |  |  | 201 |  |  |  | 254 |
Reportable segment capital expenditures |  |  | 843 |  |  |  | 890 |  |  |  | 694 |
Corporate and Other |  |  | 1,149 |  |  |  | 608 |  |  |  | 568 |
Capital expenditures |  | $ | 1,992 |  |  | $ | 1,498 |  |  | $ | 1,262 |
| (c) | Amortization of intellectual property is included in the calculation of gross margin by segment. Amortization pertaining to other types of intangible assets, such as customer relationships and trademarks, is included in general and administrative on the Consolidated Statements of Income. Within the table above, the depreciation and amortization costs that are included in calculating the gross margin of the noted segment are included; other costs such as amortization that is recorded to general and administrative expense is shown in corporate and other.
The following table sets forth net inventories by reportable segment. Our chief operating decision maker is not provided with any other segment asset information.
|  | March 31, 2021 |  |  | March 31, 2020 |
Sterilization and Disinfection Control |  | $ | 2,333 |  |  | $ | 2,104 |
Instruments |  |  | 3,253 |  |  |  | 3,065 |
Biopharmaceutical Development |  |  | 4,162 |  |  |  | 7,438 |
Continuous Monitoring |  |  | 1,430 |  |  |  | 1,623 |
Reportable segment Inventory |  |  | 11,178 |  |  |  | 14,230 |
Corporate and administrative |  |  | - |  |  |  | - |
Total inventories |  | $ | 11,178 |  |  | $ | 14,230 |
The following table sets forth a summary of long-lived assets by geographic area. Long-lived assets exclude goodwill and intangible assets acquired in a business combination.
|  | As of March 31, |
|  | 2021 |  |  | 2020 |
United States |  | $ | 21,443 |  |  | $ | 23,306 |
Foreign |  |  | 3,085 |  |  |  | 1,240 |
Total |  | $ | 24,528 |  |  | $ | 24,546 |
Revenues from external customers are attributed to individual countries based upon locations to which the product is shipped or exported, as follows:
|  | Year Ended March 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
United States |  | $ | 71,387 |  |  | $ | 66,344 |  |  | $ | 64,828 |
Foreign |  |  | 62,550 |  |  |  | 51,343 |  |  |  | 38,307 |
Total revenues |  | $ | 133,937 |  |  | $ | 117,687 |  |  | $ | 103,135 |
No customer accounts for 10% or more of our revenues. No foreign country exceeds 10% of total revenues.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration